Both Phase 3 trials reading out on the same day is unusual enough, but the more striking detail is that barzolvolimab hit every primary and key secondary endpoint in both EMBARQ-CSU1 and EMBARQ-CSU2, giving Celldex a clean sweep across its entire pivotal program in chronic spontaneous urticaria. That is the kind of dataset that makes a regulatory submission relatively straightforward to construct, and it removes the most common reason late-stage programs stall: a split readout requiring a third trial to adjudicate.
Barzolvolimab takes a different route into the disease than the current standard. Rather than blocking IgE, it binds the KIT receptor on mast cells and shuts down their function and survival directly at the source. Mast cell activation drives the hives and itch that define CSU, and patients inadequately controlled on existing therapy have had limited options beyond dose adjustment or off-label immunosuppressants. Omalizumab, which blocks IgE and received FDA approval for CSU in 2014, generated roughly $1.2 billion in CSU-specific revenue for Novartis in fiscal year 2024, so the commercial prize Celldex is aiming at is well established and large.
The dual-trial design matters clinically, not just commercially. Regulators typically want two independent confirmatory studies before approving a biologic for a chronic skin condition, and Celldex now has both. Hitting all key secondary endpoints alongside the primary means the submission can make a full efficacy case across symptom burden, itch, and disease control measures rather than relying on a single metric. Whether the safety profile across both studies holds up to the scrutiny a complete response to an NDA demands is the one material question the 8-K filing does not answer; the full data presentation will be the moment to evaluate that.
The number to track from here is the proportion of patients on barzolvolimab who achieved complete response, meaning a weekly Urticaria Activity Score of zero, because that endpoint most directly captures whether the KIT-targeting mechanism does something omalizumab cannot reliably deliver for refractory patients. If that figure lands meaningfully above what the omalizumab trial record shows for inadequately controlled patients, Celldex has a clinical argument that goes beyond mechanism and into differentiated outcomes.
Source link: https://www.sec.gov/Archives/edgar/data/744218/000110465926109465/tm2625892d1_8k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
